22
Participants
Start Date
June 30, 2015
Primary Completion Date
August 31, 2017
Study Completion Date
January 29, 2021
JBT-101
"Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
Placebo
"Part A: Once daily on Days 1-28, then twice daily on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
University of Pennsylvania Perlman School of Medicine, Philadelphia
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
University of Pennsylvania
OTHER
Corbus Pharmaceuticals Inc.
INDUSTRY